AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC
Ociperlimab and tislelizumab plus cCRT and tislelizumab plus cCRT exhibited a trend for improvement in PFS and numerically higher objective response rate compared with cCRT, with no new safety signals beyond the known profiles of immune checkpoint inhibitors and cCRT. Adding ociperlimab to tislelizumab plus cCRT was not associated with additional improvement in efficacy.
Authors
- Zhengfei Zhu (ORCID: https://orcid.org/0000-0001-7537-3619)
- Diansheng Zhong (ORCID: https://orcid.org/0000-0001-6483-8134)
- Yujuan Gao (ORCID: https://orcid.org/0000-0001-8917-2332)
- Youling Gong (ORCID: https://orcid.org/0000-0002-4182-1935)
- Seung Soo Yoo (ORCID: https://orcid.org/0000-0002-7309-9254)
- Jiangqiong Huang
- Qingsong Pang (ORCID: https://orcid.org/0000-0002-3576-6909)
- You Lü (ORCID: https://orcid.org/0000-0003-1671-1408)
- Pu Sun (ORCID: https://orcid.org/0009-0008-8105-3804)
- Yufeng Cheng (ORCID: https://orcid.org/0000-0002-4143-5399)
- Hongbo Wu
- Rong Yu (ORCID: https://orcid.org/0009-0008-0816-9587)
- Yunxia Zuo
- Tracy Dobbs
- Zinan Bao
Institutions
- Peking University (CN)
- Sichuan University (CN)
- Kyungpook National University Hospital (KR)
- Tianjin Medical University General Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shanghai Medical Information Center (CN)
- Fudan University Shanghai Cancer Center (CN)
- Peking University Cancer Hospital (CN)
- Tennessee Cancer Specialists (US)
- Beijing Enterprises (China) (CN)
- Shanghai Cancer Institute (CN)
- Sichuan Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- Shanghai Clinical Research Center (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-09-27
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100911
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00